A multicenter trial involving 527 gastric cancer patients found that those receiving enhanced recovery after surgery (ERAS) showed significantly better three-year overall survival (86.56% vs. 80.11%) and disease-free survival (79.57% vs. 69.57%) compared to conventional care. The ERAS group experienced fewer complications, shorter hospital stays, and lower medical expenses. Notably, patients with stage III cancer benefited the most from ERAS, showcasing its potential to enhance oncological outcomes in laparoscopic distal gastrectomy.
Comparative Study by Tian Y, Cao S (…) Zhou Y et 19 al. in Ann Surg
Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc.